After Morgan Stanley and Citigroup gave Edwards Lifesciences (NYSE: EW) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Suraj Kalia maintained a Buy rating on Edwards Lifesciences yesterday and set a price target of $280.00. The company’s shares closed last Thursday at $221.04.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 3.5% and a 52.2% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $243.94 average price target, implying an 11.5% upside from current levels. In a report issued on April 9, Raymond James also maintained a Buy rating on the stock with a $230.00 price target.
See today’s analyst top recommended stocks >>
Edwards Lifesciences’ market cap is currently $44.89B and has a P/E ratio of 43.70. The company has a Price to Book ratio of 16.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient’s heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient’s heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
